VIP Modulation of Hippocampal Synaptic Plasticity: A Role for VIP Receptors as Therapeutic Targets in Cognitive Decline and Mesial Temporal Lobe Epilepsy

Diana Cunha-Reis1,2* and Ana Caulino-Rocha1,2

1 BioISI - Biosystems and Integrative Sciences Institute, Faculdade de Ciências, Universidade de Lisboa, Lisbon, Portugal,
2 Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade de Lisboa, Lisbon, Portugal

Vasoactive intestinal peptide (VIP) is an important modulatory peptide throughout the CNS acting as a neurotransmitter, neurotrophic or neuroprotective factor. In the hippocampus, a brain area implicated in learning and memory processes, VIP has a crucial role in the control of GABAergic transmission and pyramidal cell activity in response to specific network activity by either VIP-containing basket cells or interneuron-selective (IS) interneurons and this appears to have a differential impact in hippocampal-dependent cognition. At the cellular level, VIP regulates synaptic transmission by either promoting disinhibition, through activation of VPAC1 receptors, or enhancing pyramidal cell excitability, through activation of VPAC2 receptors. These actions also control several important synaptic plasticity phenomena such as long-term potentiation (LTP) and long-term depression (LTD). This paper reviews the current knowledge on the activation and multiple functions of VIP expressing cells in the hippocampus and their role in controlling synaptic transmission, synaptic plasticity and learning and memory processes, discussing also the role of VPAC1 and VPAC2 VIP receptors in the regulation of these different processes. Furthermore, we address the current knowledge regarding changes in VIP mediated neurotransmission in epileptogenesis and mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE-HS), and discuss the therapeutic opportunities of using selective VIP receptor ligands to prevent epileptogenesis and cognitive decline in MTLE-HS.

Keywords: VIP, synaptic plasticity, interneurons, hippocampus, MTLE, cognition, VPAC1 receptors

INTRODUCTION

Vasoactive intestinal peptide (VIP), a 28 amino-acid residue peptide originally isolated from porcine duodenum by Mutt and Said (1974), owes its name to its powerful ability to cause vasodilatation (Said and Mutt, 1970), by promoting vascular smooth muscle relaxation in the gastrointestinal tract when released by peripheral nerves of the sympathetic nervous
shown to occur essentially through reduction of the Ca
+ +
1979). This enhancement in pyramidal cell excitability was later
the first report of its physiological actions in the CNS described
et al., 1984; Flood et al., 1990; Glowa et al., 1992). Nevertheless,
particularly in hippocampal-dependent memory traits (Cottrell
recognized to have a crucial role in mnemonic processes and
was likely an important target for VIP action. VIP was also early
expression was predominant in hippocampal GABAergic
1979; Besson et al., 1984), where VIP was
hippocampus and the hippocampus of animal models (Emson
Upon its discovery, VIP expression was reported in the human
VIP IN THE HIPPOCAMPUS
Upon its discovery, VIP expression was reported in the human
hippocampus and the hippocampus of animal models (Emson
et al., 1979; Lorén et al., 1979; Besson et al., 1984), where VIP was
also shown to bind to hippocampal membranes (Taylor and Pert, 1979; Besson et al., 1984). Shortly after, it became evident that VIP expression was predominant in hippocampal GABAergic interneurons (Köhler, 1982, 1983; Léránth et al., 1984; Kosaka et al., 1985) and that modulation of GABAergic transmission was likely an important target for VIP action. VIP was also early recognized to have a crucial role in mnemonic processes and particularly in hippocampal-dependent memory traits (Cottrell et al., 1984; Flood et al., 1990; Glowa et al., 1992). Nevertheless, the first report of its physiological actions in the CNS described VIP excitation of hippocampal CA1 neurones (Dodd et al., 1979). This enhancement in pyramidal cell excitability was later shown to occur essentially through reduction of the Ca
+ +
2
–conductance, leading to a decrease of the long-lasting afterhyperpolarization (sAHP) and a reduction of the accommodation of firing (Haas and Gähwiler, 1992). This action was postsynaptic since it prevailed in low Ca
+ +
2
, thus decreasing excitatory synaptic transmission through an increase in inhibitory transmission (Yanovsky et al., 1997). These mechanisms could not account for the previously observed increase in synaptic transmission and pyramidal cell firing (Haas and Gähwiler, 1992). In fact, VIP-mediated concomitant pre and post-synaptic enhancement of GABAergic transmission generating disinhibition of synaptic transmission to pyramidal cell dendrites (Cunha-Reis et al., 2004) appears to coexist with direct VIP mediated actions on pyramidal cell bodies either promoting enhancement glutamatergic EPSCs (Ciranna and Cavallaro, 2003) or GABAergic currents (Cunha-Reis et al., 2004) in rat hippocampal slices. The physiological relevance of these conflicting observations remains poorly understood but may be relevant in distinct physiological conditions, depending on network and behavioral state-dependent activation of different interneuron populations (Tyan et al., 2014; Detailed immunohistochemistry studies fully characterized hippocampal VIP
+ INs dendritic trees and axon projections (Acsády et al., 1996a,b), allowing the classification of VIP
+ INs into two fundamental groups according to their targets: VIP
+ basket cells are responsible for somatic inhibition of pyramidal cells, are also immunoreactive for cholecystokinin (VIP
+ - CCK
+ BCs, Figure 1) and do not express parvalbumin, as most BCs in the hippocampus. VIP
+ INs that selectively innervate other interneurons (VIP
+ IS INs) include two subtypes: (a) interneurons with cell bodies located at the stratum pyramidale (SP) or near and projecting to the stratum Oriens/Alveus border (VIP
+ IS O/A INs or type III IS cells, Figure 1), that also express the interneuron marker calretinin and target mostly somatostatin-expressing (SOM
+) interneurons innervating the distal dendrites of pyramidal cells at the stratum lucunosum-moleculare (SLM) and (b) VIP
+ INs that project their axons to the stratum radiatum (SR, VIP
+ SR SR INs, Figure 1), with cell bodies located either at the SR/SLM border (type II IS cells) or at SR/SP and targeting interneurons controlling synaptic transmission to proximal dendrites of pyramidal cells in the SR (Acsády et al., 1996a,b; Klausberger and Somogyi, 2008). In genetically modified VIP-eGFP mice, additional targets of VIP
+ IS O/A INs in the O/A, including bistratified cells and oriens-oriens INs, have been described and recently a new VIP expressing interneuron population located at the O/A (VIP
+ long-range projecting INs, VIP
+ LR P INs) was described targeting INs within the O/A in CA1 but also both INs and pyramidal cells within the subiculum (Francavilla et al., 2018). It is not clear if it is also present in the rat hippocampus.

Considering the early acquired knowledge (Acsády et al., 1996a,b) on the target selectivity of VIP-IS hippocampal interneurons in the rat, Yanovsky et al. (1997) studied the influence of VIP application to the Oriens/Alveus border and showed that in the absence of synaptic interactions, VIP increased the firing rate of these interneurons and decreased the slope of the fEPSPs recorded at the SR and SLM, thus decreasing excitatory synaptic transmission through an increase in inhibitory transmission (Yanovsky et al., 1997). These mechanisms could not account for the previously observed increase in synaptic transmission and pyramidal cell firing (Haas and Gähwiler, 1992). In fact, VIP-mediated concomitant pre and post-synaptic enhancement of GABAergic transmission generating disinhibition of synaptic transmission to pyramidal cell dendrites (Cunha-Reis et al., 2004) appears to coexist with direct VIP mediated actions on pyramidal cell bodies either promoting enhancement glutamatergic EPSCs (Ciranna and Cavallaro, 2003) or GABAergic currents (Cunha-Reis et al., 2004) in rat hippocampal slices. The physiological relevance of these conflicting observations remains poorly understood but may be relevant in distinct physiological conditions, depending on network and behavioral state-dependent activation of different interneuron populations (Tyan et al., 2014;
VIP AND VIP RECEPTORS

VIP shows structural similarity to other neuroendocrine peptides, including secretin, glucagon, gastric inhibitory peptide, growth hormone releasing factor and PACAP (Deng and Jin, 2017); and belongs glucagon–secretin–VIP family of peptides targets (Clynen et al., 2014). VIP acts through two high affinity receptors (VPAC₁ and VPAC₂) that belong to Group II receptor (GPCR) family and are encoded by two different genes sharing only 55% similarity. These have nearly the same affinity for VIP (in the low nanomolar range) (Yang et al., 2010; Harmar et al., 2012) and bind also PACAP with similar affinity, hence the name VPAC given to VIP receptors (Laburthe et al., 2002). The VIP receptor subfamily also includes a third receptor, PAC₁ (PACAP specific receptor), which binds VIP with low affinity (in the micromolar range) (Harmar et al., 2012). VPAC receptors exhibit multiple consensus sites for phosphorylation by intracellular kinases and N-glycosylation, but differences in the N-glycosylation are observed according to tissue and/or species (Laburthe et al., 2002).

Both VPAC and PAC₁ receptors are positively coupled to Gₐₛ and stimulate the cAMP/PKA signaling pathway (see Laburthe et al., 2002; Harmar et al., 2012 for review). However, PAC₁ receptors additionally strongly stimulate Gₐq and the phospholipase C (PLC)/PKC signaling pathway, while VPAC receptors activate it weakly (Harmar et al., 1998; Yang et al., 2010). However, VPAC₁ receptors can couple to Gᵢₒ proteins in the hippocampus (Shreewe, 2002) and VIP enhancement of [Ca²⁺]ᵢ in astrocyte cultures depends on IP₃ turnover (Fatatis et al., 1994).

VIP RECEPTORS AND HIPPOCAMPAL NEUROTRANSMISSION

Although VIP and PACAP receptors have a widespread expression in the brain, VPAC₁ receptors are predominantly found in the hippocampus and cerebral cortex, while VPAC₂ receptors prevail in the thalamus and suprachiasmatic nucleus, showing lower expression in the hippocampus, spinal cord, dorsal root ganglia and brainstem (Harmar et al., 2012; Borbély et al., 2013). Not surprisingly, VIP and VIP receptors are involved in learning and memory processes (Yang et al., 2010; Borbély et al., 2013), yet, elucidating the differential involvement of each VIP receptor in the actions of VIP has proven very difficult until ligands with enough selectivity to discriminate between VPAC₁ and the VPAC₂ receptor were developed (Gourlet et al., 1997a,b,c; Moreno et al., 2000). This is particularly important in the hippocampus, where both receptors are expressed (Vertongen et al., 1997; Joo et al., 2004).

VIP receptors are unevenly distributed in different hippocampal layers. VPAC₂ receptors are more expressed in SP of the Ammon’s Horn implying a key role in the modulation of hippocampal pyramidal cell activity, whereas VPAC₁ receptors are preferentially located in the SO and SR and partially co-localized with glial markers (Acsády et al., 1996a; Joo et al., 2004). No study has to date identified VPAC₁ receptors in hippocampal interneurons, yet the fact that VIP enhancement of synaptic transmission to CA1 pyramidal cells involves inhibition of GABAergic interneurons that control...
pyramidal cell dendrites, leading to disinhibition (Cunha-Reis et al., 2004), an action mediated by activation of VPAC₁ receptors (Cunha-Reis et al., 2005) preferentially located in the SO, SR or O/A (Vertongen et al., 1997; Joo et al., 2004) suggests VPAC₁ receptors are in fact responsible for VIP actions on hippocampal interneurons. VPAC₂ receptors are the main mediators of VIP enhancement of pyramidal cell excitability (Cunha-Reis et al., 2006), and likely mediators of VIP enhancement of NMDA receptor currents in pyramidal cells (Yang et al., 2009), effects that are mostly post-synaptic and independent of GABAAergic transmission (Ciranna and Cavallaro, 2003; Cunha-Reis et al., 2004), and that likely involve inhibition of the sAHP (Haas and Gähwiler, 1992) (see Table 1).

VIP modulation of hippocampal GABAAergic transmission involves both presynaptic enhancement of GABA release and postsynaptic facilitation of GABAAergic currents in interneurons (Wang et al., 1997; Cunha-Reis et al., 2004). We recently reported a dual opposing regulation of GABA release by VPAC₁ receptors in isolated hippocampal nerve terminals (Cunha-Reis et al., 2017): VPAC₁ receptors inhibit and VPAC₂ receptors enhance GABA release. VPAC₁ receptor activation inhibits voltage-gated calcium channel (VGCC)-dependent GABA exocytosis through a Gₛ/o and PKA-independent and partially PKC-dependent mechanism (Cunha-Reis et al., 2017). VPAC₂ receptor activation enhances VGCC-dependent GABA exocytosis by a Gₛ/PKA/PKC-dependent mechanism but also enhances GAT-1 carrier-mediated GABA outflow through a Gₛ/PKC-dependent mechanism. Given the asymmetry in VPAC₁ and VPAC₂ receptor location in different layers of Ammon’s horn, VIP may differentially modulate GABA release to pyramidal cells and INs, and thus have distinct

| Action                                                                 | Target                      | Receptor                      | Species/preparation                           | References                  |
|------------------------------------------------------------------------|-----------------------------|-------------------------------|-----------------------------------------------|-----------------------------|
| Enhanced pyramidal cell excitability                                   | CA1 PNs                     | Unknown                       | Rat hippocampal slices                        | Dodd et al., 1979           |
| Enhanced synaptic transmission and pyramidal cell excitibility and;     | CA1 PNs                     | Unknown                       | Male Wistar rats (young adult): hippocampal   | Haas and Gähwiler, 1992     |
| Reduced the slow afterhyperpolarization (Ca²⁺-dependent K⁺ current)    | CA1 INs and PNs             | Unknown                       | Male NMRI mice (young adult): hippocampal     | Yanovsky et al., 1997       |
| Increased the frequency of mIPSCs without affecting their mean magnitude| Hippocampal neurons         | Unknown                       | Cultured hippocampal neurons                  | Wang et al., 1997           |
| Enhanced EPSCs                                                         | CA1 PNs                     | Unknown                       | Juvenile male Wistar rats: hippocampal slices | Ciranna and Cavallaro, 2003 |
| Enhanced synaptic transmission through disinhibition and pyramidal cell excitability | CA1 PNs (dendrites and soma) CA1 INs and PNs GABAergic nerve terminals | Unknown                       | Male Wistar rats (young adult): hippocampal slices | Cunha-Reis et al., 2004 |
| Enhanced GABA release                                                  |                             |                               |                                               |                             |
| Enhanced GABA release                                                 |                             |                               |                                               |                             |
| VIP enhanced synaptic transmission                                      | CA1 PNs                     | VPAC₁ and VPAC₂ receptors     | Male Wistar rats (young adult): hippocampal slices | Cunha-Reis et al., 2005     |
| Enhances pyramidal cell excitability                                   | CA1 PNs (dendrites)         | VPAC₂ receptor                 | Male Wistar rats (young adult): hippocampal slices | Cunha-Reis et al., 2006     |
| VIP enhanced the amplitude of NMDARs                                    | CA1 PNs                     | VPAC₁/VPAC₂ receptors          | Juvenile and young adult male wistar rats: isolated CA1 neurons and hippocampal slices | Yang et al., 2009           |
| Endogenous VIP inhibits CA1 hippocampal LTD                            | CA1 PNs (dendrites)         | VPAC₁ receptor                 | Male Wistar rats (young adult): hippocampal slices | Cunha-Reis et al., 2010     |
| Endogenous VIP inhibits hippocampal CA1 LTD and depotentiation          | CA1 PNs (dendrites)         | VPAC₁ receptor                 | Juvenile and young adult male Wistar rats: hippocampal slices | Cunha-Reis et al., 2014     |
| Enhances exocytotic GABA release and GAT-1 nerve terminal reversal     | GABAergic nerve terminals    | VPAC₂ receptor                 | Male Wistar rats (young adult): isolated nerve terminals | Cunha-Reis et al., 2017     |
| Inhibits exocytotic GABA release                                       |                             | VPAC₁ receptor                 |                                               |                             |

CA₁, hippocampus Cornu Ammonis 1; GAT-1, GABA transporter 1; INs, interneurons; NMRI, Naval Medical Research Institute; O/A, hippocampal Oriens-Alveus layer; PNs, Pyramidal neurons; SR, Stratum radiatum; SLM, Stratum lacunosum-molecular; VPAC₁ and VPAC₂, VIP – Vasoactive intestinal peptide; VIP receptors 1 and 2.
consequences on synaptic transmission to pyramidal cell dendrites and pyramidal cell activity, suggesting several possible therapeutic applications.

**VIP AND SYNAPTIC PLASTICITY**

Synaptic plasticity relies on long-lasting, activity-dependent bidirectional changes in the strength of synaptic communication leading to long-term potentiation (LTP) and long-term depression (LTD) (Mellor, 2018) and is widely accepted as the cellular mechanism underlying memory storage (Bliss and Collingridge, 2019). LTP can be triggered by a single episode of high frequency stimulations (HFS), such as a tetanus or theta burst (Albensi et al., 2007; Larson and Munkácsy, 2015; Bliss and Collingridge, 2019), mimicking the firing of hippocampal principal cells during learning tasks, and was the first synaptic plasticity mode to be associated with hippocampal-dependent memory formation (Bliss and Collingridge, 2019). LTD can be elicited by low-frequency stimulation (LFS), mimicking hippocampal activity during delta waves, and is involved in hippocampal-dependent memory processes associated with behavioral flexibility like memory extinction, reversal learning, reformulation of previously formed memories, terminating/shifting attention and in stabilizing the effects of learning (Kitchigina et al., 1999; Albensi et al., 2007; Kemp and Manahan-Vaughan, 2007; Collingridge et al., 2010). Both LTP and LTD require the activation of NMDA receptors, and their stability or long-lasting expression is dependent on subsequent activation of multiple intracellular cascades (Collingridge et al., 2010; Bliss and Collingridge, 2019). LTP of glutamatergic transmission requires activation of Ca²⁺/calmodulin-dependent protein kinase II (CaMKII) and recruitment and insertion of AMPA receptors into the postsynaptic membrane (early-LTP) (Park et al., 2018; Benke and Traynelis, 2019). Endurance and stability of LTD is believed to require synaptic contact enlargement and both PKA activity and de novo protein synthesis (late-LTP) (Park et al., 2018; Bliss and Collingridge, 2019).

Recent evidence supports the view that disinhibition plays a crucial role in regulating hippocampal synaptic plasticity (Artinian and Lacaille, 2018). Furthermore, Yang et al. (2009) showed that exogenously applied VIP enhances NMDA currents in CA1 pyramidal cells, an effect mimicked by VPAC2 and to a lesser extent by VPAC1 selective agonists. This suggests that either endogenous VIP or PACAP, the two endogenous agonists of this receptor, could contribute to NMDA-dependent hippocampal synaptic plasticity such as LTP, LTD and depotentiation. We recently described that endogenous VIP, through VPAC1 receptor activation, modulates the NMDA receptor-dependent LTD and depotentiation in the CA1 area of the hippocampus (Cunha-Reis et al., 2014). Furthermore, disinhibition achieved through inhibition of VPAC1 receptors was more efficient than blockade of GABAA-mediated transmission in revealing LTD, suggesting that SR interneurons are fundamental in restraining synaptic adaptations underlying expression of LTD. VPAC1 receptor activation by endogenous VIP also enhances hippocampal LTP induced by TBS, an action that is dependent on GABAergic transmission and involves phosphorylation of GluA1 AMPA subunit by CaMKII, a fundamental mechanism for receptor synaptic recruitment (Cunha-Reis et al., 2010; Carmo and Cunha-Reis, 2011; Cunha-Reis and Carmo, 2011) (see Table 1). Activation of hippocampal VPAC2 (but not VPAC1) receptors also promotes phosphorylation of GluA1 at Ser845 (Toda and Huganir, 2015), a PKA target site that is implicated in LTP maintenance and late-LTP (Benke and Traynelis, 2019).

VIP and PACAP modulation of hippocampal principal cell activity targets (directly or indirectly) both the dendritic and somatic compartments implicating these peptides in regulation of both Hebbian and homeostatic plasticity (Wefelmeyer et al., 2016; Yee et al., 2017; Foncelle et al., 2018), yet the physiological and behaviorally relevant stimuli for this modulation are still largely uncovered. Recently, it was described that VIP+ IS INs are activated by both Schaffer collateral and commissural excitatory fibers, being recruited fundamentally during theta oscillations but not during fast ripples (Luo et al., 2020), suggesting a fundamental role in information gating during spatial navigation and memory encoding. Accordingly, VIP+ IS INs are targeted by medium raphe serotonergic and GABAergic projections and septal cholinergic fibers, fundamental for the pacing, engagement and suppression of hippocampal theta rhythm (Vinogradova et al., 1999; Borhegyi et al., 2004; Vandecasteele et al., 2014).

Release of large dense core vesicles containing neuropeptides is known to require high-intensity repetitive stimulation, unlike release of small synaptic vesicles containing fast transmitters such as glutamate or GABA (Ghijsen and Leenders, 2005). Firing of VIP-containing interneurons locked with theta rhythm may suffice to release endogenous VIP from hippocampal nerve terminals.

**VIP IN COGNITIVE PROCESSES**

Early from its discovery, VIP was described to have a crucial role in mnemonic processes and particularly in hippocampal-dependent memory traits. In particular, endogenous VIP was implicated in spatial learning in the Morris water maze (Glowa et al., 1992; Takashima et al., 1993a; Itoh et al., 1994), avoidance learning in the T-maze (Flood et al., 1990) or the shuttle box, together with reduced rearing exploratory behavior (Cottrell et al., 1984; Takashima et al., 1993b), suggesting that VIP is mainly involved in regulating motivated learning behavior. VIP has lateralized effects on the modulation of exploratory behavior and passive avoidance learning (Ivanova et al., 2008, 2009) and anxiolytic and anti-depressive effects (Ivanova et al., 2014), and rescues deficits in hippocampal-dependent passive avoidance learning tasks in a rat model of depression. Recently, VIP-mediated hippocampal disinhibition of pyramidal cell activity was shown to play a crucial role in goal-directed spatial learning tasks (Turi et al., 2019).
VIP-KO mice show decreased expression of VPAC$_2$ and to a lesser extent VPAC$_1$ receptors together with strong circadian rhythm disruption and enhanced arousal and hyperactivity in the open-field test (Girard et al., 2006). Furthermore, VIP-deficient mice shows impaired recall and reversal learning in a fear conditioning test and deficits in social behavior (Chaudhury et al., 2008; Stack et al., 2008). VPAC$_2$-KO mice display normal acquisition of fear conditioning, contextual and cued fear memory, but impaired extinction of cued fear memory (Ago et al., 2017).

VIP participates in the pathophysiology of several neurological disorders associated with cognitive dysfunction, like depression (Ivanova et al., 2012), autism spectrum disorders, Alzheimer's disease (AD), Parkinson's disease (PD) and epilepsy (de Lanerolle et al., 1995; Hill, 2007; White et al., 2010). Due to its anti-apoptotic, anti-inflammatory and neuroprotective actions, VIP and its receptors constitute promising therapeutic targets in many of these pathologies (Gozes, 2001; Delgado et al., 2002; Yu et al., 2017).

VIP, SEIZURES, AND EPILEPSY

Epilepsy is the most common, chronic neurological disease (Devinsky et al., 2018) and is characterized by the incidence of recurrent, unprovoked seizures with associated cognitive, psychological and social disturbances (Clynen et al., 2014; Devinsky et al., 2018). According to its underlying causes epilepsy is classified into genetic or idiopathic. More than 500 genes are associated with predisposition to develop epilepsy (Devinsky et al., 2018). Idiopathic epilepsy, has unknown causes but often follows several possible precipitating events such as head trauma, stroke, brain hypoxia, infectious/autoimmune diseases, tumors or childhood febrile seizures (Clynen et al., 2014).

Mesial temporal-lobe epilepsy with hippocampal sclerosis (MTLE-HS), the most prevalent form of symptomatic focal epilepsy, is a heavy burden for the healthcare system. Many MTLE-HS patients are refractory to treatment with multiple anti-epileptic drugs, and amygdalohippocampectomy surgery is the last intervention to prevent complex partial seizures (Kuang et al., 2014). Declarative memory deficits (Helmstaedter and Kockelmann, 2006) are also a hallmark of MTLE-HS, that can be further aggravated by hippocampal removal. Most MTLE cases are idiopathic and evidence suggests that precipitating events trigger epileptogenesis by generating aberrant synaptic plasticity/neuronal excitability, excitotoxicity, secondary non-convulsive status epilepticus, inflammation and generation of reactive oxygen species (ROS) (Devinsky et al., 2018; Rana and Musto, 2018), ultimately leading to occurrence of spontaneous recurrent seizures. MTLE-HS is characterized by hippocampal sclerosis, massive neuronal loss and severe astrogliosis (Thom, 2014). Enhanced neurogenesis initially drives formation of new neural pathways in epileptogenesis (Beck and Yaari, 2008), but is impaired in MTLE-HS chronic phase (Zhong et al., 2016). Impaired LTP, due to pathological saturation (Beck et al., 2000), is a major cause for cognitive impairment in MTLE-HS, but changes in input/output neuronal electrical properties (El-Hassar et al., 2007a) and inhibitory/excitatory balance also occur from early in epileptogenesis (El-Hassar et al., 2007b). New drug targets able to control seizures or preventing epileptogenesis are an urgent need (Clynen et al., 2014).

Neuropeptides, such as VIP, are stored in large dense-core granules and are released during the sustained high-frequency activity (5–40 Hz) occurring during epileptiform activity, being implicated in regulation of seizure susceptibility, constituting appealing targets for the development of new AEDs, potentially less susceptible to side-effects (Clynen et al., 2014).

VIP is an important regulator of hippocampal activity through both direct actions on pyramidal cell excitability (Haas and Gähwiler, 1992) and by regulating synaptic transmission and synaptic plasticity to pyramidal cell dendrites through disinhibition (Cunha-Reis et al., 2004, 2010, 2014; Cunha-Reis and Carmo, 2011; Luo et al., 2020), actions that have a major impact on hippocampal-dependent learning and memory formation (Turi et al., 2019).

In human MTLE-HS, an up-regulation in VIP receptors in the seizure focus (hippocampus) was linked to the loss of principal neurons (i.e., granule cells and pyramidal neurons) without changes in the pattern and distribution of VIP$^+$ INs (de Lanerolle et al., 1995). Accordingly, an enhancement in VIP$^+$ INs has been described in a mouse model of temporal lobe epilepsy (TLE) (King and LaMotte, 1988) and decreased dendritic but not somatic GABAergic inhibition has been implicated in different animal models of experimental TLE (Sloviter, 1987; Cossart et al., 2001). Although an enhancement in disinhibition caused by VIP could be implicated in reduced seizure threshold in MTLE-HS, enhancement in VIP expression is more likely a compensatory mechanism for the selective loss of OLM interneurons in TLE, the main targets of VIP$^+$ IS O/A INs. Recently, it was described that while the overall density of the VIP$^+$ IS O/A INs was preserved, the number of their synaptic contacts in CA1 O/A was reduced in the pilocarpine model of TLE and was accompanied by significant alterations in their dendritic morphology and passive membrane properties (David and Topolnik, 2017).

Following kainic acid and pentylentetrazole-induced seizures in rodents, an early short-term decrease in hippocampal VIP levels following the initial (precipitating) seizures was described (Marksteiner et al., 1989; Romualdi et al., 1992), suggesting that transient changes in VIP expression either contribute or counteract selective interneuron loss and plasticity changes during latent-period epileptogenesis. Preliminary studies in vitro show that changes in synaptic plasticity and synaptic plasticity markers following brief insults like hypoxia, bicuculline-induced seizures or inter-ictal like activity are either prevented or enhanced by a VPAC$_1$ receptor antagonist, suggesting that different epileptogenic events are differentially regulated by VPAC$_1$ receptor activity (Cunha-Reis, 2013; Carvalho-Rosa and Cunha-Reis, 2019).

In MTLE patients, the up-regulation of VIP receptors observed chronically is consistent with an increase in surviving neurons and levels of reactive glia (de Lanerolle et al., 1995;
Clynen et al., 2014), suggesting that VPAC receptors (especially VPAC1) are promising targets for preventing epileptogenesis, a process that extends beyond the initial latent period (Devinsky et al., 2018). Given their role in the control of hippocampal synaptic plasticity they constitute also excellent candidates for prevention or attenuation of cognitive decline in MTLE. Furthermore, the dual role of VPAC1 and VPAC2 receptors in the control of hippocampal GABA release makes them the perfect targets for development of drugs aiming to control the imbalance in GABAergic and glutamatergic transmission associated with TLE (Schousboe et al., 2014; Cunha-Reis et al., 2017).

**CONCLUDING REMARKS**

In conclusion, the importance of VIP, acting through VPAC1 or VPAC2 Rs, either to the control of hippocampal disinhibition leading to enhanced synaptic transmission or promoting a direct enhancement of pyramidal cell excitability suggests that VIP can have a differential impact in hippocampal-dependent cognition, and its possible therapeutic applications should be explored. The up-regulation of VIP receptors observed in MTLE patients and the finding obtained in animal models that the interneuron targets of VIP-containing interneurons are particularly susceptible to epileptic damage, suggest that VPAC receptors (especially VPAC1) are promising targets for epileptogenesis prevention and for prevention or attenuation of cognitive decline in MTLE.

**AUTHOR CONTRIBUTIONS**

AC-R: writing – review and editing. DC-R: resources, supervision, funding acquisition, project administration, and writing – original draft, review and editing.

**FUNDING**

This work was supported national and international funding managed by the Fundação para a Ciência e a Tecnologia (FCT, IP), Portugal. Grants: UIDB/04046/2020 and UIDP/04046/2020 centre grants (to BioISI) and research grant FCT/POCTI (PTDC/SAUPUB/28311/2017) EPIRaft grant (to DC-R). Researcher contract: Norma Transitória – DL57/2016/CP1479/CT0044 to DC-R.
peptide VPAC1 receptors. *Hippocampus* 24, 1533–1563. doi: 10.1002/hipo.22316

Cunha-Reis, D., and Carmo, A. J. (2011). Correlation of VIP VPAC(1) modulation of GluR1 phosphorylation and inhibition of protein kinases in theta-burst LTP experiments with data mining tools. *Amino Acids* 41,543.

Cunha-Reis, D., Ribeiro, J. A., de Almeida, R. F. M. M., and Sebastião, A. M. (2017). VPAC1 and VPAC2 receptor activation on GABA release from hippocampal nerve terminals involve several different signalling pathways. *Br. J. Pharmacol.* 174, 4725–4737. doi: 10.1111/bph.14051

Cunha-Reis, D., Ribeiro, J. A., and Sebastião, A. M. (2005). VP enhances synaptic transmission to hippocampal CA1 pyramidal cells through activation of both VPAC1 and VPAC2 receptors. *Brain Res.* 1049, 52–60. doi: 10.1016/j.brainres.2005.04.077

Cunha-Reis, D., Ribeiro, J. A., and Sebastião, A. M. (2006). VPAC2 receptor activation mediates VP enhancement of population spikes in the CA1 area of the hippocampus. *Ann. N. Y. Acad. Sci.* 1070, 210–214. doi: 10.1196/annals.1317.016

Cunha-Reis, D., Rodrigues, N. C., and Ribeiro, J. A. (2010). On the cellular and molecular pathways involved in the inhibition of LTP in the CA1 area of the hippocampus. *J. Mol. Neurosci.* 42:278.

Cunha-Reis, D., Sebastião, A. M., Wirkner, K., Illes, P., and Ribeiro, J. A. (2004). VP enhances both pre- and postsynaptic GABAergic transmission to hippocampal interneurons leading to increased excitatory synaptic transmission to CA1 pyramidal cells. *Br. J. Pharmacol.* 143, 733–744. doi: 10.1016/j.bcp.2004.07.009

David, L. S., and Topolnik, L. (2017). Target-specific alterations in the inhibitory drive to hippocampal GABAergic cells after status epilepticus. *Exp. Neurol.* 292, 102–112. doi: 10.1016/j.expneurol.2017.03.007

de Lanerolle, N. C., Gunel, M., Sundaresan, S., Shen, M. Y., Brines, M. L., and Spencer, D. D. (1995). Vasoactive intestinal polypeptide and its receptor changes in human temporal lobe epilepsy. *Brain Res.* 686, 182–193. doi: 10.1016/0006-8993(95)00365-w

Delgado, M., Jonakait, G. M., and Ganea, D. (2002). Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia. *Glia* 39, 148–161. doi: 10.1002/glia.10098

Deng, G., and Jin, L. (2017). The effects of vasoactive intestinal peptide in neurodegenerative disorders. *NeuroL. Res.* 39, 65–72. doi: 10.1080/01616412.2016.1250458

Devinsky, O., Vezzani, A., O’Brien, T. J., Jette, N., Scheffer, I. E., De Curtis, M., et al. (2018). *Epilepsy*. *Nat. Rev. Dis. Primers* 4:18024. doi: 10.1038/s41571-018-0070-z

Dodd, J., Kelly, J. S., and Said, S. I. (1979). Excitation of CA1 neurones of the rat hippocampus by the octacosapeptide, vasoactive intestinal polypeptide (VIP): distribution in normal human brain and in Huntington’s disease. *J. Physiol.* 173, 174ñ178. doi: 10.1113/jphysiol.1979.sp005297

El-Hassar, L., Milh, M., Wendling, F., Ferrand, N., Esclapez, M., and Bernard, C. (2006). Noncompensation in peptide/receptor gene expression and distinct neurochemical characteristics of VIP-immunoreactive interneurons in the rat dentate gyrus. *Eur. J. Neurosci.* 8, 1415–1431. doi: 10.1111/j.1460-9586.1996.tb01604.x

Harmar, A. J., Arimura, A., Gozes, I., Journot, L., Laburthe, M., Pisegna, J. R., et al. (1998). International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. *Pharmacol. Rev.* 50, 265–270. doi: 10.1016/S0196-9781(00)004-4525-0

Harmar, A. J., Fahrenkrug, J., Gozes, I., Laburthe, M., May, V., Pisegna, J. R., et al. (2012). Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR Review 1. *Br. J. Pharmacol.* 166, 4–17. doi: 10.1111/j.1476-5381.2012.01871.x

Haug, T., and Storm, J. F. (2000). Protein kinase a mediates the modulation of the slow Ca2+-dependent K+ current, IA74, by the neuropeptides CRF, VIP, and CGRP in hippocampal pyramidal neurons. *J. Neurophysiol.* 83, 2071–2079. doi: 10.1152/jn.2000.83.4.2071

Helmstaedter, C., and Kochelmann, E. (2006). Cognitive outcomes in patients with chronic temporal lobe epilepsy. *Epilepsia* 47(Suppl. 2), 96–98. doi: 10.1111/j.1528-1167.2006.00702.x

Hill, J. M. (2007). Vasoactive intestinal peptide in neurodevelopmental disorders: therapeutic potential. *Curr. Pharm. Des.* 13, 1079–1089. doi: 10.2174/138161207780818975

Itoh, S., Takahama, A., and Morimoto, T. (1994). Impaired spatial learning by vasoactive intestinal peptide in Morris water maze task in the rat. *Can. J. Physiol. Pharmacol.* 72, 25–29. doi: 10.1139/y94-005

Ivanova, M., Belcheva, S., Belcheva, I., Negrev, N., and Tashev, R. (2012). Lateralized hippocampal effects of vasoactive intestinal peptide on learning and memory in rats in a model of depression. *Psychopharmacology (Berl).* 212, 561–574. doi: 10.1007/s00213-011-2600-1

Ivanova, M., Belcheva, S., Belcheva, I., Stoyanov, Z., and Tashev, R. (2014). Modulatory effect of VIP injected into hippocampal CA1 area on anxiety in olfactory bulbectomized rats. *Acta Neurobiol. Exp.* 74, 317–327.

Ivanova, M., Ternianov, A., Belcheva, S., Tashev, R., Negrev, N., and Belcheva, I. (2008). Hippocampal asymmetry in exploratory behavior to vasoactive intestinal polypeptide. *Peptides* 29, 940–947. doi: 10.1016/j.peptides.2008.01.016

Ivanova, M., Ternianov, A., Tashev, R., Belcheva, S., and Belcheva, I. (2009). Lateralized learning and memory effects of vasoactive intestinal peptide infused into the rat hippocampal CA1 area. *Regul. Pept.* 156, 42–46. doi: 10.1016/j.regpep.2009.05.009
Köhler, C. (1983). A morphological analysis of vasoactive intestinal polypeptide.

Laburthe, M., Couvineau, A., and Marie, J. C. (2002). VPAC receptors for VIP and

Léránth, C., Frotscher, M., Tömböl, T., and Palkovits, M. (1984). Ultrastructure and

Luo, X., Guet-McCreight, A., Villette, V., Francavilla, R., Marino, B., Chamberland,

King, J. T., and LaMotte, C. C. (1988). VIP-, SS-, and GABA-like immunoreactivity

Marksteiner, J., Sperk, G., and Maas, D. (1989). Differential increases in brain

Kemp, A., and Manahan-Vaughan, D. (2007). Hippocampal long-term depression:

Mutt, V., and Said, S. I. (1974). Structure of the porcine vasoactive

Miyata, A., Arimura, A., Dahl, R. R., Minamino, N., Uehara, A., Jiang, L.,

Mellor, J. (2018). “Synaptic plasticity at hippocampal synapses: experimental background,” in Hippocampal Microcircuits. Springer Series in Computational Neuroscience, eds V. Cutsuridis, B. Graham, S. Cobb, and I. Vida, (Cham: Springer), 13ñ30. doi: 10.1007/978-3-319-08894-5_2

Sloviter, R. S. (1987). Decreased hippocampal inhibition and a selective loss of interneurons in experimental epilepsy. Science 235, 73–76. doi: 10.1126/science.2879352

Stack, C. M., Lim, M. A., Cusay, K., Stone, M. M., Seibert, K. M., Spivak-Pohis, L., et al. (2008). Deficits in social behavior and reversal learning are more prevalent in male offspring of VIP deficient female mice. Exp. Neurosci. 21, 67–84. doi: 10.1611/exn.2008.01.003

Takashima, A., Maeda, Y., and Itoh, S. (1993a). Influence of chronic intracerebroventricular infusion of vasoactive intestinal peptide (VIP) on memory processes in Morris water pool test in the rat. Peptides 14, 1073–1078. doi: 10.1016/0196-9718(93)90089-y

Takashima, A., Maeda, Y., and Itoh, S. (1993b). Vasoactive intestinal peptide (VIP) causes memory impairment in passive avoidance responding of the rat. Peptides 14, 1067–1071. doi: 10.1016/0196-9718(93)90088-x

Taylor, D. P., and Pert, C. B. (1979). Vasoactive intestinal peptide: Specific binding to rat brain membranes. Proc. Natl. Acad. Sci. U.S.A. 76, 660–664. doi: 10.1073/pnas.76.2.660

Thom, M. (2014). Review: hippocampal sclerosis in epilepsy: a neuropathology review. Neuropathol. Appl. Neurobiol. 40, 520–543. doi: 10.1111/nan.12150

Toda, A. M. A., and Huganir, R. L. (2015). Regulation of AMPA receptor phosphorylation by the neuropeptide PACAP38. Proc. Natl. Acad. Sci. U.S.A. 25, 6712–6717. doi: 10.1073/pnas.1507229112

Turi, G. F., Li, W. K., Chavlis, S., Pandi, I., O’Hare, J., Priestley, J. B., et al. (2019). Vasoactive intestinal polypeptide-expressing interneurons in the hippocampus support goal-oriented spatial learning. Neuron 101, 1150–1165.e8. doi: 10.1016/j.neuron.2019.01.009

Tyan, L., Chamberland, S., Magnin, E., Camiré, O., Francavilla, R., Suzanne David, L., et al. (2014). Dendritic inhibition provided by interneuron-specific cells controls the firing rate and timing of the hippocampal feedback inhibitory circuitry. J. Neurosci. 34, 4534–4547. doi: 10.1523/JNEUROSCI.3813-13.2014

Vandecasteele, M., Varga, V., Berényi, A., Papp, E., Barthó, P., Venance, L., et al. (2014). Optogenetic activation of septal cholinergic neurons suppresses sharp wave ripples and enhances theta oscillations in the hippocampus. Proc. Natl. Acad. Sci. U.S.A. 111, 13535–13540. doi: 10.1073/pnas.1411233111

Vertongen, P., Schiffmann, S. N., Gourlet, P., and Robberecht, P. (1997). Autoradiographic visualization of the receptor subclasses for vasoactive intestinal polypeptide (VIP) in rat brain. Peptides 18, 1547–1554. doi: 10.1016/s0196-9718(97)00229-5

Vishnoi, O. S., Kichtchiga, V. F., Kudina, T. A., and Zhenchenko, K. I. (1999). Spontaneous activity and sensory responses of hippocampal neurons during persistent theta-rhythm evoked by median raphe nucleus blockade in rabbit. Neuroscience 94, 745–753. doi: 10.1016/s0306-4522(99)00253-5
Wang, H.-L., Li, A., and Wu, T. (1997). Vasoactive intestinal polypeptide enhances the GABAergic synaptic transmission in cultured hippocampal neurons. Brain Res. 746, 294–300. doi: 10.1016/S0006-8993(96)00772-X

Weifelmeyer, W., Puhl, C. J., and Burrone, J. (2016). Homeostatic plasticity of subcellular neuronal structures: from inputs to outputs. Trends Neurosci. 39, 656–667. doi: 10.1016/j.tins.2016.08.004

White, M., Ji, S., Cai, H., Maudsley, S., and Martin, R. (2010). Therapeutic potential of vasoactive intestinal peptide and its receptors in neurological disorders. CNS Neurol. Disord. Drug Targets 9, 661–666. doi: 10.2174/187152710793361595

Yang, K., Lei, G., Jackson, M. F., and MacDonald, J. F. (2010). The involvement of PACAP/VIP system in the synaptic transmission in the hippocampus. J. Mol. Neurosci. 42, 319–326. doi: 10.1007/s12031-010-9372-7

Yang, K., Trepanier, C. H., Li, H., Beazely, M. A., Lerner, E. A., Jackson, M. F., et al. (2009). Vasoactive intestinal peptide acts via multiple signal pathways to regulate hippocampal NMDA receptors and synaptic transmission. Hippocampus 19, 779–789. doi: 10.1002/hipo.20559

Yanovsky, Y., Sergeeva, O. A., Freund, T. F., and Haas, H. L. (1997). Activation of interneurons at the stratum oriens/alveus border suppresses excitatory transmission to apical dendrites in the CA1 area of the mouse hippocampus. Neuroscience 77, 87–96. doi: 10.1016/s0306-4522(96)00461-7

Yee, A. X., Hsu, Y. T., and Chen, L. (2017). A metaplasticity view of the interaction between homeostatic and hebbian plasticity. Philos. Trans. R. Soc. B Biol. Sci. 372, 20160155. doi: 10.1098/rstb.2016.0155

Yu, R., Liu, H., Peng, X., Cui, Y., Song, S., Wang, L., et al. (2017). The palmitoylation of the N-terminal extracellular Cys37 mediates the nuclear translocation of VPAC1 contributing to its antiapoptotic activity. Oncotarget 8, 42728–42741. doi: 10.18632/oncotarget.17449

Zhong, Q., Ren, B.-X., and Tang, F.-R. (2016). Neurogenesis in the hippocampus of patients with temporal lobe epilepsy. Curr. Neurol. Neurosci. Rep. 16:20. doi: 10.1007/s11910-015-0616-3

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.